市場調査レポート
商品コード
1491989

カスタム抗体市場:サービス別、タイプ別、由来別、用途別、適応症別、エンドユーザー別、地域別 - 2029年までの予測

Custom Antibody Market by Service (Development, Purification, Fragmentation, Labeling), Type (mAbs, pAbs, rAbs), Source (Rabbit, Mice), Application (Research, Therapeutics), Indication (Oncology, Immunology, Infectious, CVD) - Global Forecast to 2029

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 377 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
カスタム抗体市場:サービス別、タイプ別、由来別、用途別、適応症別、エンドユーザー別、地域別 - 2029年までの予測
出版日: 2024年06月05日
発行: MarketsandMarkets
ページ情報: 英文 377 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

カスタム抗体市場は、予測期間中に9.2%のCAGRで拡大し、2024年の5億7,900万米ドルから2029年には9億100万米ドルに達すると予測されています。

調査範囲
調査対象年 2022年~2029年
基準年 2023年
予測期間 2024年~2029年
検討単位 金額(100万米ドル)
セグメント サービス別、タイプ別、由来別、用途別、適応症別、エンドユーザー別、地域別
対象地域 北米、欧州、アジア太平洋、中東・アフリカ、ラテンアメリカ、GCC諸国

この市場の成長は、がん、自己免疫疾患、感染症などの慢性疾患の有病率の上昇により、標的を絞った効果的な治療用抗体の需要が高まっていることに起因しています。バイオテクノロジーと遺伝子工学の進歩により、カスタム抗体の開発と生産が大幅に改善され、その特異性と有効性が高まっています。

カスタム抗体のサービス別市場は、抗体開発、抗体生産・精製、抗体断片化・標識に区分されます。抗体開発はさらに抗原調製、免疫・ハイブリドーマ作製、抗体特性解析に細分化されます。2023年、世界のカスタム抗体市場では、抗体開発分野がサービス分野で最大のシェアを占めました。抗体薬物複合体(ADC)などのドラッグデリバリーシステムにおける抗体の使用の増加などの要因が、カスタム抗体開発のニーズを拡大しています。

アジア太平洋は予測期間中、最も高い成長率で成長すると予想されます。新興経済国、慢性疾患の有病率の上昇、先進医療を受ける患者層の多さなど、さまざまな要因がAPAC市場の高成長を後押ししています。

当レポートでは、世界のカスタム抗体市場について調査し、サービス別、タイプ別、由来別、用途別、適応症別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
  • 顧客のビジネスに影響を与える動向/混乱
  • 規制状況
  • バリューチェーン分析
  • 技術分析
  • 価格分析
  • 特許分析
  • サプライチェーン分析
  • エコシステム分析
  • 2024年~2025年の主な会議とイベント
  • ポーターのファイブフォース分析
  • 主な利害関係者と購入基準
  • 投資と資金調達のシナリオ

第6章 カスタム抗体市場、サービス別

  • イントロダクション
  • 抗体開発
  • 抗体の生産と精製
  • 抗体の断片化と標識

第7章 カスタム抗体市場、タイプ別

  • イントロダクション
  • モノクローナル抗体
  • ポリクローナル抗体
  • 組み換え抗体
  • その他

第8章 カスタム抗体市場、由来別

  • イントロダクション
  • マウス
  • ウサギ
  • その他

第9章 カスタム抗体市場、用途別

  • イントロダクション
  • 研究
  • 治療

第10章 カスタム抗体市場、適応症別

  • イントロダクション
  • 腫瘍
  • 感染症
  • 免疫
  • 神経生物
  • 心血管疾患
  • その他

第11章 カスタム抗体市場、エンドユーザー別

  • イントロダクション
  • 製薬会社・バイオテクノロジー企業
  • 学術研究機関
  • CRO

第12章 カスタム抗体市場、地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東
  • アフリカ

第13章 競合情勢

  • イントロダクション
  • 主要参入企業が採用した戦略/秘策
  • 収益分析
  • 市場シェア分析
  • ブランド/サービス比較分析
  • 企業評価マトリックス:主要参入企業、2023年
  • 企業評価マトリックス:スタートアップ/中小企業、2023年
  • カスタム抗体サービスベンダーの評価と財務指標
  • 競合シナリオ

第14章 企業プロファイル

  • 主要参入企業
    • THERMO FISHER SCIENTIFIC INC.
    • GENSCRIPT
    • BIO-RAD LABORATORIES, INC.
    • MERCK KGAA
    • AGILENT TECHNOLOGIES, INC.
    • REVVITY, INC.
    • BIO-TECHNE
    • ROCKLAND IMMUNOCHEMICALS, INC.
    • LABORATORY CORPORATION OF AMERICA HOLDINGS
    • INOTIV
    • DANAHER CORPORATION
    • SINO BIOLOGICAL, INC.
    • KANEKA CORPORATION
    • ORIGENE TECHNOLOGIES, INC.
    • ABSOLUTE BIOTECH
    • BIOINTRON BIOLOGICS
  • その他の企業
    • CELL SIGNALING TECHNOLOGY, INC.
    • CURIA GLOBAL, INC.
    • MABTECH
    • ACROBIOSYSTEMS
    • ELABSCIENCE BIONOVATION INC.
    • CREATIVE DIAGNOSTICS
    • CUSABIO TECHNOLOGY LLC
    • BIOGENES GMBH
    • RAYBIOTECH, INC.
    • PROTEINTECH GROUP, INC.
    • IMGENEX INDIA PVT. LTD.
    • SYNBIO TECHNOLOGIES
    • PROSCI INCORPORATED
    • CREATIVE BIOLABS

第15章 付録

目次
Product Code: BT 6817

The custom antibody market is expected to reach USD 901 million in 2029 from USD 579 million in 2024, at a CAGR of 9.2% during the forecast period.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD) Million
SegmentsType, Technology, Specimen, End User, and region
Regions coveredNorth America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries

The growth of this market can be attributed to the increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and infectious diseases, which has heightened the demand for targeted and effective therapeutic antibodies. Advancements in biotechnology and genetic engineering have significantly improved the development and production of custom antibodies, enhancing their specificity and efficacy.

"The antibody development segment accounted for the largest share by service in the custom antibody market 2023."

The custom antibody market by service is segmented into antibody development, antibody production & purification, and antibody fragmentation & labeling. The antibody development is further subsegmented into antigen preparation, immunization & hybridoma production, and antibody characterization. In 2023, the antibody development segment accounted for the largest share of the service segment in the global custom antibody market. Factors such as the increasing use of antibodies in drug delivery systems, such as antibody-drug conjugates (ADCs), has expanded the need for custom antibody development.

"The Asia Pacific region is growing at the highest CAGR in the custom antibody market from 2024 to 2029."

The Asia Pacific region is expected to grow at the highest growth rate during the forecast period. Various factors including emerging economies, increased prevalence of chronic diseases, and large patient pool undergoing advanced medical treatment are factors driving the high growth of the APAC market.

Increased research investments from government funding are expected to boost the growth of the custom antibody market in the Asia Pacific region. As the region continues to invest in drug development, there is a growing demand for research antibodies driving demand for custom antibodies.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side 30%
  • By Designation: C-level Executives - 55%, Director-level - 20%, and Others - 25%
  • By Region: North America -45%, Europe -20%, Asia-Pacific -20%, Latin America -10%, Middle East -3%, and Africa-2%.

List of Companies Profiled in the Report:

  • Thermo Fisher Scientific Inc. (US)
  • GenScript (US)
  • Merck KGaA (Germany)
  • Bio-Rad Laboratories, Inc. (US)
  • Agilent Technologies, Inc. (US)
  • Revvity, Inc. (US)
  • Bio-Techne (US)
  • ROCKLAND IMMUNOCHEMICALS, INC. (US)
  • Laboratory Corporation of America Holdings (US)
  • Inotiv (US)
  • Danaher Corporation (US)
  • Sino Biological, Inc. (China)
  • KANEKA CORPORATION (Japan)
  • OriGene Technologies, Inc. (US)
  • Absolute Biotech (US)
  • Biointron Biologics (China)
  • Cell Signaling Technology, Inc. (US)
  • Curia Global, Inc. (US)
  • Mabtech (Sweden)
  • ACROBiosystems (US)
  • Elabscience Bionovation Inc. (US)
  • Creative Diagnostics (US)
  • CUSABIO TECHNOLOGY LLC (US)
  • BioGenes GmbH (Germany)
  • RayBiotech, Inc. (US)
  • Proteintech Group, Inc (US)
  • IMGENEX INDIA Pvt Ltd. (India)
  • Synbio Technologies (US)
  • ProSci Incorporated (US)
  • Creative Biolabs (US)

Research Coverage:

This research report categorizes the custom antibody market by service (antibody development (antigen preparation, immunization & hybridoma production, and antibody characterization), antibody production & purification, and antibody fragmentation & labeling, type (monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and others), source (mice, rabbits, and others), application (research, and therapeutics), indication (oncology, infectious diseases, immunology, neurobiology, cardiovascular diseases, and other indications), end user (pharmaceutical & biotechnologies companies, academic & research institutes, and contract research organizations), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The report provides in-depth information on significant factors influencing the growth of the custom antibody market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches, and acquisitions within the custom antibody market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall custom antibody market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (growing importance of custom antibodies in precision medicine, use of antibodies in biomarker identification and validation, rising research activities and funding investments for antibody development, advancement in biotechnology and genetic engineering), restraints (High cost and time-consuming antibody development from transgenic animals), opportunities (rising therapeutic and diagnostic application of antibodies, high scope for growth in emerging economies), and challenges (challenges associated with safety and stability) influencing the growth of the market.

  • Product Development/Innovation: Detailed insights on newly launched services of the custom antibody market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the custom antibody market
  • Competitive Assessment: Thermo Fisher Scientific Inc. (US), GenScript (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Revvity, Inc. (US), Bio-Techne (US), ROCKLAND IMMUNOCHEMICALS, INC. (US), Laboratory Corporation of America Holdings (US), Inotiv (US), Danaher Corporation (US), Sino Biological, Inc. (China), KANEKA CORPORATION (Japan), OriGene Technologies, Inc. (US), Absolute Biotech (US), Biointron Biologics (China), Cell Signaling Technology, Inc. (US), Curia Global, Inc. (US), Mabtech (Sweden), ACROBiosystems (US), Elabscience Bionovation Inc. (US), Creative Diagnostics (US), CUSABIO TECHNOLOGY LLC (US), BioGenes GmbH (Germany), RayBiotech, Inc. (US), Proteintech Group, Inc (US), IMGENEX INDIA Pvt Ltd. (India), Synbio Technologies (US), ProSci Incorporated (US), Creative Biolabs (US) among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 REGIONS COVERED
  • 1.4 YEARS CONSIDERED
  • 1.5 CURRENCY CONSIDERED
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES
  • 1.8 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 CUSTOM ANTIBODY MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • FIGURE 3 CUSTOM ANTIBODY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
    • 2.2.1 MARKET ESTIMATION
    • FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
    • FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2023)
      • 2.2.1.1 Insights of primary experts
    • FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
    • 2.2.2 SEGMENTAL MARKET SIZE ESTIMATION
    • FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • 2.3 MARKET GROWTH RATE PROJECTIONS
    • FIGURE 8 CUSTOM ANTIBODY MARKET: CAGR PROJECTIONS
    • TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 LIMITATIONS
  • 2.7 RISK ANALYSIS
  • 2.8 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

    • FIGURE 10 CUSTOM ANTIBODY MARKET, BY SERVICE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 11 CUSTOM ANTIBODY MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 12 CUSTOM ANTIBODY MARKET, BY SOURCE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 13 CUSTOM ANTIBODY MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION)
    • FIGURE 14 CUSTOM ANTIBODY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
    • FIGURE 15 GEOGRAPHICAL SNAPSHOT OF CUSTOM ANTIBODY MARKET

4 PREMIUM INSIGHTS

  • 4.1 CUSTOM ANTIBODY MARKET OVERVIEW
    • FIGURE 16 GROWING IMPORTANCE OF CUSTOM ANTIBODIES IN PRECISION MEDICINE TO DRIVE GROWTH
  • 4.2 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SERVICE AND COUNTRY (2023)
    • FIGURE 17 ANTIBODY DEVELOPMENT SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC CUSTOM ANTIBODY MARKET IN 2023
  • 4.3 CUSTOM ANTIBODY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • 4.4 CUSTOM ANTIBODY MARKET SHARE, BY END USER, 2023
    • FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2023

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 20 CUSTOM ANTIBODY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 2 CUSTOM ANTIBODY MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing importance of custom antibodies in precision medicine
      • 5.2.1.2 Use of antibodies in biomarker identification and validation
      • 5.2.1.3 Rising research activities and funding investments for antibody development
      • 5.2.1.4 Advancements in biotechnology and genetic engineering
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost and time-consuming antibody development from transgenic animals
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Rising therapeutic and diagnostic application of antibodies
      • 5.2.3.2 High scope for growth in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Challenges associated with safety and stability
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 21 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.4 REGULATORY LANDSCAPE
    • 5.4.1 REGULATORY SCENARIO
    • 5.4.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 3 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 4 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 5 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 6 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 22 CUSTOM ANTIBODY MARKET: VALUE CHAIN ANALYSIS
  • 5.6 TECHNOLOGICAL ANALYSIS
    • 5.6.1 KEY TECHNOLOGIES
      • 5.6.1.1 Hybridoma technology
      • 5.6.1.2 Phage display technology
      • 5.6.1.3 Recombinant DNA technology
    • 5.6.2 COMPLIMENTARY TECHNOLOGIES
      • 5.6.2.1 Next-generation sequencing
      • 5.6.2.2 High-throughput screening
    • 5.6.3 ADJACENT TECHNOLOGIES
      • 5.6.3.1 Single-cell analysis technology
      • 5.6.3.2 Peptide synthesis
      • 5.6.3.3 Protein engineering
  • 5.7 PRICING ANALYSIS
    • 5.7.1 INDICATIVE PRICING ANALYSIS, BY SERVICE, 2023 & 2024
    • TABLE 7 INDICATIVE PRICE ANALYSIS, BY SERVICE, 2023 & 2024
    • 5.7.2 INDICATIVE PRICING ANALYSIS, BY REGION, 2023 & 2024
    • TABLE 8 INDICATIVE PRICE ANALYSIS, BY REGION, 2023 & 2024
  • 5.8 PATENT ANALYSIS
    • 5.8.1 METHODOLOGY
    • 5.8.2 PATENTS FILED, BY DOCUMENT TYPE, 2014-2024
    • TABLE 9 PATENTS FILED, 2014-2024
    • 5.8.3 INNOVATION AND PATENT APPLICATIONS
    • FIGURE 23 TOTAL NUMBER OF PATENTS GRANTED, 2014-2024
    • 5.8.4 TOP APPLICANTS
    • FIGURE 24 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014-2024
    • TABLE 10 TOP 20 PATENT OWNERS IN CUSTOM ANTIBODY MARKET, 2014-2024
    • TABLE 11 INDICATIVE LIST OF PATENTS IN CUSTOM ANTIBODY MARKET, 2022-2024
  • 5.9 SUPPLY CHAIN ANALYSIS
    • FIGURE 25 CUSTOM ANTIBODY MARKET: SUPPLY CHAIN ANALYSIS
  • 5.10 ECOSYSTEM ANALYSIS
    • FIGURE 26 CUSTOM ANTIBODY MARKET: ECOSYSTEM ANALYSIS
    • 5.10.1 CUSTOM ANTIBODY RAW MATERIAL SUPPLIERS
    • TABLE 12 CUSTOM ANTIBODY MARKET: RAW MATERIAL SUPPLIERS
    • 5.10.2 CUSTOM ANTIBODY SERVICE PROVIDERS
    • TABLE 13 CUSTOM ANTIBODY MARKET: SERVICE PROVIDERS
    • 5.10.3 CUSTOM ANTIBODY END USERS
    • TABLE 14 CUSTOM ANTIBODY MARKET: END USERS
    • 5.10.4 CUSTOM ANTIBODY REGULATORY AUTHORITIES
    • TABLE 15 CUSTOM ANTIBODY MARKET: REGULATORY AUTHORITIES
  • 5.11 KEY CONFERENCES AND EVENTS, 2024-2025
    • TABLE 16 CUSTOM ANTIBODY MARKET: LIST OF CONFERENCES AND EVENTS, 2024-2025
  • 5.12 PORTER'S FIVE FORCES ANALYSIS
    • FIGURE 27 CUSTOM ANTIBODY MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.12.1 IMPACT OF PORTER'S FIVE FORCES ON CUSTOM ANTIBODY MARKET
    • TABLE 17 CUSTOM ANTIBODY MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.12.2 INTENSITY OF COMPETITIVE RIVALRY
    • 5.12.3 BARGAINING POWER OF SUPPLIERS
    • 5.12.4 BARGAINING POWER OF BUYERS
    • 5.12.5 THREAT OF SUBSTITUTES
    • 5.12.6 THREAT OF NEW ENTRANTS
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CUSTOM ANTIBODIES
    • 5.13.2 CUSTOM ANTIBODY MARKET: BUYING CRITERIA FOR END USERS
    • FIGURE 29 KEY BUYING CRITERIA FOR END USERS OF CUSTOM ANTIBODIES
    • TABLE 18 BUYING CRITERIA FOR CUSTOM ANTIBODIES, BY END USER
  • 5.14 INVESTMENT AND FUNDING SCENARIO
    • TABLE 19 RESEARCH FUNDING BY VARIOUS INSTITUTES/CENTERS, 2020-2024 (USD MILLION)

6 CUSTOM ANTIBODY MARKET, BY SERVICE

  • 6.1 INTRODUCTION
    • TABLE 20 CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
  • 6.2 ANTIBODY DEVELOPMENT
    • TABLE 21 CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 22 CUSTOM ANTIBODY DEVELOPMENT MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 23 NORTH AMERICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 24 EUROPE: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 25 ASIA PACIFIC: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 26 LATIN AMERICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 27 MIDDLE EAST: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 28 GCC COUNTRIES: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • 6.2.1 ANTIBODY CHARACTERIZATION
      • 6.2.1.1 Growing adoption of therapeutic antibodies to drive growth
    • TABLE 29 ANTIBODY CHARACTERIZATION MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 30 NORTH AMERICA: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 31 EUROPE: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 32 ASIA PACIFIC: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 33 LATIN AMERICA: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 34 MIDDLE EAST: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 35 GCC COUNTRIES: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • 6.2.2 ANTIGEN PREPARATION
      • 6.2.2.1 Rising use of research antibodies to support market growth
    • TABLE 36 ANTIGEN PREPARATION MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 37 NORTH AMERICA: ANTIGEN PREPARATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 38 EUROPE: ANTIGEN PREPARATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 39 ASIA PACIFIC: ANTIGEN PREPARATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 40 LATIN AMERICA: ANTIGEN PREPARATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 41 MIDDLE EAST: ANTIGEN PREPARATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 42 GCC COUNTRIES: ANTIGEN PREPARATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • 6.2.3 IMMUNIZATION & HYBRIDOMA PRODUCTION
      • 6.2.3.1 Rising demand for therapeutic antibodies to drive market
    • TABLE 43 IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 44 NORTH AMERICA: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 45 EUROPE: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 46 ASIA PACIFIC: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 47 LATIN AMERICA: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 48 MIDDLE EAST: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 49 GCC COUNTRIES: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.3 ANTIBODY PRODUCTION & PURIFICATION
    • 6.3.1 RESEARCH & DEVELOPMENT IN LIFE SCIENCES TO BOOST MARKET GROWTH
    • TABLE 50 CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 51 NORTH AMERICA: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 52 EUROPE: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 53 ASIA PACIFIC: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 54 LATIN AMERICA: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 55 MIDDLE EAST: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 56 GCC COUNTRIES: CUSTOM ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.4 ANTIBODY FRAGMENTATION & LABELING
    • 6.4.1 RISING RESEARCH AND CLINICAL APPLICATIONS TO DRIVE GROWTH
    • TABLE 57 CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 58 NORTH AMERICA: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 59 EUROPE: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 60 ASIA PACIFIC: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 61 LATIN AMERICA: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 62 MIDDLE EAST: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 63 GCC COUNTRIES: CUSTOM ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)

7 CUSTOM ANTIBODY MARKET, BY TYPE

  • 7.1 INTRODUCTION
    • TABLE 64 CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • 7.2 MONOCLONAL ANTIBODIES
    • 7.2.1 HIGH DEGREE OF SENSITIVITY AND PRECISION TO BOOST MARKET GROWTH
    • TABLE 65 CUSTOM MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 66 NORTH AMERICA: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 67 EUROPE: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 68 ASIA PACIFIC: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 69 LATIN AMERICA: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 70 MIDDLE EAST: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 71 GCC COUNTRIES: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.3 POLYCLONAL ANTIBODIES
    • 7.3.1 VERSATILITY AND EFFICACY IN RECOGNITION OF ANTIGEN SITES TO BOOST MARKET GROWTH
    • TABLE 72 CUSTOM POLYCLONAL ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 73 NORTH AMERICA: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 74 EUROPE: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 75 ASIA PACIFIC: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 76 LATIN AMERICA: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 77 MIDDLE EAST: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 78 GCC COUNTRIES: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.4 RECOMBINANT ANTIBODIES
    • 7.4.1 RISING RESEARCH & DEVELOPMENT IN LIFE SCIENCES INDUSTRY TO BOOST MARKET GROWTH
    • TABLE 79 CUSTOM RECOMBINANT ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 80 NORTH AMERICA: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 81 EUROPE: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 82 ASIA PACIFIC: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 83 LATIN AMERICA: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 84 MIDDLE EAST: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 85 GCC COUNTRIES: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.5 OTHER CUSTOM ANTIBODIES
    • TABLE 86 OTHER CUSTOM ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 87 NORTH AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 88 EUROPE: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 89 ASIA PACIFIC: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 90 LATIN AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 91 MIDDLE EAST: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 92 GCC COUNTRIES: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)

8 CUSTOM ANTIBODY MARKET, BY SOURCE

  • 8.1 INTRODUCTION
    • TABLE 93 CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • 8.2 MICE
    • 8.2.1 WIDESPREAD AVAILABILITY AND COST-EFFECTIVENESS TO PROPEL MARKET
    • TABLE 94 CUSTOM ANTIBODY MARKET FOR MICE, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 95 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 96 EUROPE: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 97 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 98 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 99 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 100 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.3 RABBITS
    • 8.3.1 ABILITY TO GENERATE HIGH ANTIBODY DIVERSITY WITH OPTIMAL AFFINITY TO DRIVE MARKET
    • TABLE 101 CUSTOM ANTIBODY MARKET FOR RABBITS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 102 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 103 EUROPE: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 104 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 105 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 106 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 107 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.4 OTHER SOURCES
    • TABLE 108 CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 109 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 110 EUROPE: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 111 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 112 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 113 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 114 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)

9 CUSTOM ANTIBODY MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 115 CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • 9.2 RESEARCH
    • 9.2.1 HIGH DEGREE OF SENSITIVITY AND SPECIFICITY TO BOOST MARKET GROWTH
    • TABLE 116 CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 117 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 118 EUROPE: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 119 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 120 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 121 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 122 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 9.3 THERAPEUTIC
    • 9.3.1 RISING DEMAND FOR ANTIBODY-BASED THERAPEUTICS TO SUPPORT MARKET GROWTH
    • TABLE 123 CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 124 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 125 EUROPE: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 126 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 127 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 128 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 129 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)

10 CUSTOM ANTIBODY MARKET, BY INDICATION

  • 10.1 INTRODUCTION
    • TABLE 130 CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
  • 10.2 ONCOLOGY
    • 10.2.1 RISING PREVALENCE OF CANCER TO DRIVE MARKET
    • TABLE 131 CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 132 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 133 EUROPE: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 134 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 135 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 136 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 137 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • 10.3 INFECTIOUS DISEASES
    • 10.3.1 USE OF ANTIBODIES IN VACCINE & THERAPEUTIC DEVELOPMENT TO BOOST MARKET GROWTH
    • TABLE 138 CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 139 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 140 EUROPE: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 141 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 142 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 143 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 144 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 10.4 IMMUNOLOGY
    • 10.4.1 RISING NUMBER OF PRODUCTS UNDER CLINICAL STUDIES TO BOOST MARKET GROWTH
    • TABLE 145 CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 146 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 147 EUROPE: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 148 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 149 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 150 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 151 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • 10.5 NEUROBIOLOGY
    • 10.5.1 RISING DEMAND FOR ANTIBODIES IN NEURODEGENERATIVE DISEASES TO PROPEL MARKET
    • TABLE 152 CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 153 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 154 EUROPE: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 155 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 156 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 157 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 158 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • 10.6 CARDIOVASCULAR DISEASES
    • 10.6.1 RISING DEMAND FOR CVD BIOMARKERS TO DRIVE MARKET
    • TABLE 159 CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 160 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 161 EUROPE: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 162 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 163 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 164 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 165 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 10.7 OTHER INDICATIONS
    • TABLE 166 CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 167 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 168 EUROPE: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 169 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 170 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 171 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 172 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)

11 CUSTOM ANTIBODY MARKET, BY END USER

  • 11.1 INTRODUCTION
    • TABLE 173 CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 11.2.1 RISING DEMAND FOR THERAPEUTIC ANTIBODIES TO BOOST MARKET GROWTH
    • TABLE 174 CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 175 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 176 EUROPE: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 177 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 178 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 179 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 180 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 11.3 ACADEMIC & RESEARCH INSTITUTES
    • 11.3.1 GROWING INDUSTRY-ACADEMIA COLLABORATIONS TO DRIVE MARKET
    • TABLE 181 CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 182 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 183 EUROPE: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 184 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 185 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 186 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 187 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 11.4 CONTRACT RESEARCH ORGANIZATIONS
    • 11.4.1 INCREASING DEMAND FOR MABS AND ADC SERVICES TO PROPEL MARKET
    • TABLE 188 CUSTOM ANTIBODY MARKET FOR CROS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 189 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 190 EUROPE: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 191 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 192 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 193 MIDDLE EAST: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 194 GCC COUNTRIES: CUSTOM ANTIBODY MARKET FOR CROS, BY COUNTRY, 2022-2029 (USD MILLION)

12 CUSTOM ANTIBODY MARKET, BY REGION

  • 12.1 INTRODUCTION
    • TABLE 195 CUSTOM ANTIBODY MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 12.2 NORTH AMERICA
    • FIGURE 30 NORTH AMERICA: CUSTOM ANTIBODY MARKET SNAPSHOT
    • TABLE 196 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 197 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 198 NORTH AMERICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 199 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 200 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 201 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 202 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 203 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.2.1 US
      • 12.2.1.1 Growing number of FDA approvals for monoclonal antibody therapies to drive market
    • FIGURE 31 NIH FUNDING IN LAST 10 YEARS FOR HEALTHCARE R&D (2014-2024)
    • TABLE 204 US: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 205 US: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 206 US: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 207 US: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 208 US: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 209 US: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 210 US: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.2.2 CANADA
      • 12.2.2.1 Increasing incidence of cancer to support market growth
    • TABLE 211 CANADA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 212 CANADA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 213 CANADA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 214 CANADA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 215 CANADA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 216 CANADA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 217 CANADA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.2.3 NORTH AMERICA: RECESSION IMPACT
  • 12.3 EUROPE
    • TABLE 218 EUROPE: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 219 EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 220 EUROPE: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 221 EUROPE: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 222 EUROPE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 223 EUROPE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 224 EUROPE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 225 EUROPE: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.3.1 GERMANY
      • 12.3.1.1 Growing investment in ADCs development to drive market
    • TABLE 226 GERMANY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 227 GERMANY: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 228 GERMANY: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 229 GERMANY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 230 GERMANY: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 231 GERMANY: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 232 GERMANY: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.3.2 UK
      • 12.3.2.1 Life sciences funding with biotech firms to boost adoption of custom antibodies
    • TABLE 233 UK: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 234 UK: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 235 UK: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 236 UK CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 237 UK: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 238 UK: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 239 UK: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.3.3 FRANCE
      • 12.3.3.1 Increasing government investments in pharmaceutical industry to drive growth
    • TABLE 240 FRANCE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 241 FRANCE: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 242 FRANCE: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 243 FRANCE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 244 FRANCE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 245 FRANCE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 246 FRANCE: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.3.4 ITALY
      • 12.3.4.1 Rising research activities in pharma R&D to boost market growth
    • TABLE 247 ITALY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 248 ITALY: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 249 ITALY: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 250 ITALY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 251 ITALY: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 252 ITALY: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 253 ITALY: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.3.5 SPAIN
      • 12.3.5.1 Growing focus on advancements in personalized medicine to support market growth
    • TABLE 254 SPAIN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 255 SPAIN: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 256 SPAIN: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 257 SPAIN: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 258 SPAIN: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 259 SPAIN: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 260 SPAIN: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.3.6 REST OF EUROPE
    • TABLE 261 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 262 REST OF EUROPE: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 263 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 264 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 265 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 266 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 267 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.3.7 EUROPE: RECESSION IMPACT
  • 12.4 ASIA PACIFIC
    • FIGURE 32 ASIA PACIFIC: CUSTOM ANTIBODY MARKET SNAPSHOT
    • TABLE 268 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 269 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 270 ASIA PACIFIC: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 271 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 272 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 273 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 274 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 275 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.4.1 CHINA
      • 12.4.1.1 Rising prevalence of cardiovascular diseases and cancer to support market growth
    • TABLE 276 CHINA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 277 CHINA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 278 CHINA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 279 CHINA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 280 CHINA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 281 CHINA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 282 CHINA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.4.2 JAPAN
      • 12.4.2.1 Increasing research activities for development of ADCs to drive market
    • TABLE 283 JAPAN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 284 JAPAN: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 285 JAPAN: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 286 JAPAN: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 287 JAPAN: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 288 JAPAN: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 289 JAPAN: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.4.3 INDIA
      • 12.4.3.1 Favorable scenario for foreign direct investment to propel market
    • TABLE 290 INDIA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 291 INDIA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 292 INDIA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 293 INDIA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 294 INDIA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 295 INDIA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 296 INDIA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.4.4 SOUTH KOREA
      • 12.4.4.1 Increased research & development of drugs to support market growth
    • TABLE 297 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 298 SOUTH KOREA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 299 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 300 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 301 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 302 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 303 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.4.5 AUSTRALIA
      • 12.4.5.1 Increasing demand for innovative research solutions to propel market
    • TABLE 304 AUSTRALIA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 305 AUSTRALIA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 306 AUSTRALIA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 307 AUSTRALIA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 308 AUSTRALIA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 309 AUSTRALIA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 310 AUSTRALIA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.4.6 REST OF ASIA PACIFIC
    • TABLE 311 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 312 REST OF ASIA PACIFIC: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 313 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 314 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 315 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 316 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 317 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.4.7 ASIA PACIFIC: RECESSION IMPACT
  • 12.5 LATIN AMERICA
    • TABLE 318 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 319 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 320 LATIN AMERICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 321 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 322 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 323 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 324 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 325 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.5.1 BRAZIL
      • 12.5.1.1 Increased government investments in pharmaceutical R&D to drive market
    • TABLE 326 BRAZIL: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 327 BRAZIL: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 328 BRAZIL: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 329 BRAZIL: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 330 BRAZIL: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 331 BRAZIL: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 332 BRAZIL: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.5.2 MEXICO
      • 12.5.2.1 Rising demand for chronic disease treatment to support market growth
    • TABLE 333 MEXICO: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 334 MEXICO: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 335 MEXICO: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 336 MEXICO: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 337 MEXICO: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 338 MEXICO: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 339 MEXICO: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.5.3 REST OF LATIN AMERICA
    • TABLE 340 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 341 REST OF LATIN AMERICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 342 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 343 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 344 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 345 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 346 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.5.4 LATIN AMERICA: RECESSION IMPACT
  • 12.6 MIDDLE EAST
    • TABLE 347 MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 348 MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 349 MIDDLE EAST: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 350 MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 351 MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 352 MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 353 MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 354 MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.6.1 GCC COUNTRIES
    • TABLE 355 GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 356 GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 357 GCC COUNTRIES: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 358 GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 359 GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 360 GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 361 GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 362 GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
      • 12.6.1.1 Saudi Arabia
        • 12.6.1.1.1 Growing healthcare expenditure to boost market growth
    • TABLE 363 SAUDI ARABIA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 364 SAUDI ARABIA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 365 SAUDI ARABIA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 366 SAUDI ARABIA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 367 SAUDI ARABIA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 368 SAUDI ARABIA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 369 SAUDI ARABIA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
      • 12.6.1.2 UAE
        • 12.6.1.2.1 Rising government funding to propel market
    • TABLE 370 UAE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 371 UAE: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 372 UAE: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 373 UAE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 374 UAE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 375 UAE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 376 UAE: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
      • 12.6.1.3 Rest of GCC countries
    • TABLE 377 REST OF GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 378 REST OF GCC COUNTRIES: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 379 REST OF GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 380 REST OF GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 381 REST OF GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 382 REST OF GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 383 REST OF GCC COUNTRIES: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.6.2 REST OF MIDDLE EAST
    • TABLE 384 REST OF MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 385 REST OF MIDDLE EAST: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 386 REST OF MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 387 REST OF MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 388 REST OF MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 389 REST OF MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 390 REST OF MIDDLE EAST: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 12.6.3 MIDDLE EAST: RECESSION IMPACT
  • 12.7 AFRICA
    • 12.7.1 GROWING MARKET FOR PHARMACEUTICALS AND INCREASING DEMAND FOR DRUGS TO SUPPORT MARKET GROWTH
    • TABLE 391 AFRICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2022-2029 (USD MILLION)
    • TABLE 392 AFRICA: CUSTOM ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 393 AFRICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 394 AFRICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 395 AFRICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 396 AFRICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 397 AFRICA: CUSTOM ANTIBODY MARKET, BY END USER, 2022-2029 (USD MILLION)

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
  • 13.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN
    • TABLE 398 OVERVIEW OF STRATEGIES ADOPTED BY KEY CUSTOM ANTIBODY COMPANIES
  • 13.3 REVENUE ANALYSIS
    • FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN CUSTOM ANTIBODY MARKET, 2019-2023 (USD BILLION)
  • 13.4 MARKET SHARE ANALYSIS
    • FIGURE 34 CUSTOM ANTIBODY MARKET SHARE ANALYSIS, BY KEY PLAYER (2023)
    • TABLE 399 CUSTOM ANTIBODY MARKET: DEGREE OF COMPETITION
  • 13.5 BRAND/SERVICE COMPARATIVE ANALYSIS
    • FIGURE 35 BRAND/SERVICE COMPARATIVE ANALYSIS
    • 13.5.1 THERMO FISHER SCIENTIFIC INC.
    • 13.5.2 GENSCRIPT
    • 13.5.3 BIO-RAD LABORATORIES, INC.
    • 13.5.4 MERCK KGAA
    • 13.5.5 AGILENT TECHNOLOGIES, INC.
  • 13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 13.6.1 STARS
    • 13.6.2 EMERGING LEADERS
    • 13.6.3 PERVASIVE PLAYERS
    • 13.6.4 PARTICIPANTS
    • FIGURE 36 CUSTOM ANTIBODY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
    • 13.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • FIGURE 37 CUSTOM ANTIBODY MARKET: COMPANY FOOTPRINT
    • TABLE 400 CUSTOM ANTIBODY MARKET: REGION FOOTPRINT
    • TABLE 401 CUSTOM ANTIBODY MARKET: SERVICE FOOTPRINT
    • TABLE 402 CUSTOM ANTIBODY MARKET: TYPE FOOTPRINT
    • TABLE 403 CUSTOM ANTIBODY MARKET: APPLICATION FOOTPRINT
    • TABLE 404 CUSTOM ANTIBODY MARKET: INDICATION FOOTPRINT
  • 13.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 13.7.1 PROGRESSIVE COMPANIES
    • 13.7.2 RESPONSIVE COMPANIES
    • 13.7.3 DYNAMIC COMPANIES
    • 13.7.4 STARTING BLOCKS
    • FIGURE 38 CUSTOM ANTIBODY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
    • 13.7.5 COMPETITIVE BENCHMARKING
    • TABLE 405 CUSTOM ANTIBODY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
    • TABLE 406 CUSTOM ANTIBODY MARKET: COMPANY FOOTPRINT (STARTUPS/SMES)
  • 13.8 VALUATION AND FINANCIAL METRICS OF CUSTOM ANTIBODY SERVICE VENDORS
    • FIGURE 39 EV/EBITDA OF KEY VENDORS
    • FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • 13.9 COMPETITIVE SCENARIO
    • 13.9.1 DEALS
    • TABLE 407 CUSTOM ANTIBODY MARKET: DEALS, JANUARY 2021-APRIL 2024
    • 13.9.2 EXPANSIONS
    • TABLE 408 CUSTOM ANTIBODY MARKET: EXPANSIONS, JANUARY 2021-APRIL 2024

14 COMPANY PROFILES

  • 14.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 14.1.1 THERMO FISHER SCIENTIFIC INC.
    • TABLE 409 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
    • FIGURE 41 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
    • TABLE 410 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED
    • TABLE 411 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-APRIL 2024
    • 14.1.2 GENSCRIPT
    • TABLE 412 GENSCRIPT: COMPANY OVERVIEW
    • FIGURE 42 GENSCRIPT: COMPANY SNAPSHOT (2023)
    • TABLE 413 GENSCRIPT: SERVICES OFFERED
    • TABLE 414 GENSCRIPT: DEALS, JANUARY 2021-APRIL 2024
    • TABLE 415 GENSCRIPT: EXPANSIONS, JANUARY 2021-APRIL 2024
    • 14.1.3 BIO-RAD LABORATORIES, INC.
    • TABLE 416 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
    • FIGURE 43 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 417 BIO-RAD LABORATORIES, INC.: SERVICES OFFERED
    • TABLE 418 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2021-APRIL 2024
    • 14.1.4 MERCK KGAA
    • TABLE 419 MERCK KGAA: COMPANY OVERVIEW
    • FIGURE 44 MERCK KGAA: COMPANY SNAPSHOT (2023)
    • TABLE 420 MERCK KGAA: SERVICES OFFERED
    • TABLE 421 MERCK KGAA: DEALS, JANUARY 2021-APRIL 2024
    • TABLE 422 MERCK KGAA: EXPANSIONS, JANUARY 2021-APRIL 2024
    • 14.1.5 AGILENT TECHNOLOGIES, INC.
    • TABLE 423 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
    • FIGURE 45 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 424 AGILENT TECHNOLOGIES, INC.: SERVICES OFFERED
    • 14.1.6 REVVITY, INC.
    • TABLE 425 REVVITY, INC.: COMPANY OVERVIEW
    • FIGURE 46 REVVITY, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 426 REVVITY, INC.: SERVICES OFFERED
    • TABLE 427 REVVITY, INC.: DEALS, JANUARY 2021-APRIL 2024
    • 14.1.7 BIO-TECHNE
    • TABLE 428 BIO-TECHNE: COMPANY OVERVIEW
    • FIGURE 47 BIO-TECHNE: COMPANY SNAPSHOT (2023)
    • TABLE 429 BIO-TECHNE: SERVICES OFFERED
    • TABLE 430 BIO-TECHNE: DEALS, JANUARY 2021-APRIL 2024
    • 14.1.8 ROCKLAND IMMUNOCHEMICALS, INC.
    • TABLE 431 ROCKLAND IMMUNOCHEMICALS, INC.: COMPANY OVERVIEW
    • TABLE 432 ROCKLAND IMMUNOCHEMICALS, INC.: SERVICES OFFERED
    • TABLE 433 ROCKLAND IMMUNOCHEMICALS, INC.: DEALS, JANUARY 2021-APRIL 2024
    • 14.1.9 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • TABLE 434 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW
    • FIGURE 48 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2023)
    • TABLE 435 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICES OFFERED
    • 14.1.10 INOTIV
    • TABLE 436 INOTIV: COMPANY OVERVIEW
    • FIGURE 49 INOTIV.: COMPANY SNAPSHOT (2023)
    • TABLE 437 INOTIV: SERVICES OFFERED
    • TABLE 438 INOTIV: DEALS, JANUARY 2021-APRIL 2024
    • TABLE 439 INOTIV: EXPANSIONS, JANUARY 2021-APRIL 2024
    • 14.1.11 DANAHER CORPORATION
    • TABLE 440 DANAHER CORPORATION: COMPANY OVERVIEW
    • FIGURE 50 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
    • TABLE 441 DANAHER CORPORATION: SERVICES OFFERED
    • TABLE 442 DANAHER CORPORATION: DEALS, JANUARY 2021-APRIL 2024
    • TABLE 443 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021-APRIL 2024
    • 14.1.12 SINO BIOLOGICAL, INC.
    • TABLE 444 SINO BIOLOGICAL, INC.: COMPANY OVERVIEW
    • FIGURE 51 SINO BIOLOGICAL, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 445 SINO BIOLOGICAL, INC.: SERVICES OFFERED
    • TABLE 446 SINO BIOLOGICAL, INC.: DEALS, JANUARY 2021-APRIL 2024
    • TABLE 447 SINO BIOLOGICAL, INC.: EXPANSIONS, JANUARY 2021-APRIL 2024
    • 14.1.13 KANEKA CORPORATION
    • TABLE 448 KANEKA CORPORATION: COMPANY OVERVIEW
    • FIGURE 52 KANEKA CORPORATION: COMPANY SNAPSHOT (2022)
    • TABLE 449 KANEKA CORPORATION: SERVICES OFFERED
    • 14.1.14 ORIGENE TECHNOLOGIES, INC.
    • TABLE 450 ORIGENE TECHNOLOGIES, INC.: COMPANY OVERVIEW
    • TABLE 451 ORIGENE TECHNOLOGIES, INC.: SERVICES OFFERED
    • 14.1.15 ABSOLUTE BIOTECH
    • TABLE 452 ABSOLUTE BIOTECH: COMPANY OVERVIEW
    • TABLE 453 ABSOLUTE BIOTECH: SERVICES OFFERED
    • TABLE 454 ABSOLUTE BIOTECH: DEALS, JANUARY 2021-APRIL 2024
    • TABLE 455 ABSOLUTE BIOTECH: EXPANSIONS, JANUARY 2021-APRIL 2024
    • 14.1.16 BIOINTRON BIOLOGICS
    • TABLE 456 BIONTRON BIOLOGICS: COMPANY OVERVIEW
    • TABLE 457 BIOINTRON BIOLOGICS: SERVICES OFFERED
    • TABLE 458 BIOINTRON BIOLOGICS: DEALS, JANUARY 2021-APRIL 2024
  • 14.2 OTHER PLAYERS
    • 14.2.1 CELL SIGNALING TECHNOLOGY, INC.
    • TABLE 459 CELL SIGNALING TECHNOLOGY, INC.: COMPANY OVERVIEW
    • 14.2.2 CURIA GLOBAL, INC.
    • TABLE 460 CURIA GLOBAL, INC.: COMPANY OVERVIEW
    • 14.2.3 MABTECH
    • TABLE 461 MABTECH: COMPANY OVERVIEW
    • 14.2.4 ACROBIOSYSTEMS
    • TABLE 462 ACROBIOSYSTEMS: COMPANY OVERVIEW
    • 14.2.5 ELABSCIENCE BIONOVATION INC.
    • TABLE 463 ELABSCIENCE BIONOVATION INC.: COMPANY OVERVIEW
    • 14.2.6 CREATIVE DIAGNOSTICS
    • TABLE 464 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW
    • 14.2.7 CUSABIO TECHNOLOGY LLC
    • TABLE 465 CUSABIO TECHNOLOGY LLC: COMPANY OVERVIEW
    • 14.2.8 BIOGENES GMBH
    • TABLE 466 BIOGENES GMBH: COMPANY OVERVIEW
    • 14.2.9 RAYBIOTECH, INC.
    • TABLE 467 RAYBIOTECH, INC.: COMPANY OVERVIEW
    • 14.2.10 PROTEINTECH GROUP, INC.
    • TABLE 468 PROTEINTECH GROUP, INC.: COMPANY OVERVIEW
    • 14.2.11 IMGENEX INDIA PVT. LTD.
    • TABLE 469 IMGENEX INDIA PVT. LTD.: COMPANY OVERVIEW
    • 14.2.12 SYNBIO TECHNOLOGIES
    • TABLE 470 SYNBIO TECHNOLOGIES: COMPANY OVERVIEW
    • 14.2.13 PROSCI INCORPORATED
    • TABLE 471 PROSCI INCORPORATED: COMPANY OVERVIEW
    • 14.2.14 CREATIVE BIOLABS
    • TABLE 472 CREATIVE BIOLABS: COMPANY OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS